A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
eribulin mesIlate
NCT01327885, EU, CTR, 2010-024483-17
Soft Tissue Sarcoma
Phase 3
No restrictions. Note: In the ICF for Brazil there is a reference for the requirements of the local law only - but as Eisai is sharing data with the researchers based on a contract with confidentiality requirements, it is fine.
November 2017